Contact Us

Immunology Expertise

Expanding on our global experience in immunology.

Providing affordable and high-quality health care to patients coping with chronic diseases is an integral part of Fresenius Kabi’s purpose, and this is demonstrated by our long-term commitment toward developing a comprehensive portfolio of immunology biosimilars. Our biosimilars are produced in an established European facility with over 20 years’ experience in manufacturing biologics.1


We have launched biosimilars in more than
30 countries to date

3 years

Our adalimumab biosimilar has been in market in many countries since 2019

Parenteral nutrition support

Gastroenterologists may also know Fresenius Kabi as the U.S. market leader of lipid injectable emulsions2

Small molecules

Our small molecule portfolio includes several agents used in the immunology space, such as dexamethasone and methotrexate*

In immunology, our pipeline includes biosimilars of adalimumab (an anti TNF alpha monoclonal antibody which is used to treat many autoimmune diseases), tocilizumab and others. In the field of biosimilars, Fresenius Kabi is continuously committed to developing new medicines in these important therapeutic areas; we have multiple candidates in various development phases, in both the autoimmune and oncology therapeutic areas.

Discover more about how biosimilars are manufactured here.

Oncology experience
Discover a rich portfolio developed over a quarter of a century. Read More

*Full product descriptions and safety information can be found at
  1., retrieved 04/2022
  2. Data on file 4/1/22 calculation includes all ILEs approved in the U.S.
Advanced science, manufacturing and support for biosimilars